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Abstract
Background: Patients admitted to intensive care units (ICU) with acute respiratory failure (ARF) face chronic complications
that can impede return to normal daily function. A mobile, collaborative critical care model may enhance the recovery of
ARF survivors.
Methods: The Mobile Critical Care Recovery Program (m-CCRP) study is a two arm, randomized clinical trial. We will
randomize 620 patients admitted to the ICU with acute respiratory failure requiring mechanical ventilation in a 1:1 ratio
to one of two arms (310 patients per arm) – m-CCRP intervention versus attention control. Those in the intervention
group will meet with a care coordinator after hospital discharge in predetermined intervals to aid in the recovery process.
Baseline assessments and personalized goal setting will be used to develop an individualized care plan for each patient
after discussion with an interdisciplinary team. The attention control arm will receive printed material and telephone
reminders emphasizing mobility and management of chronic conditions. Duration of the intervention and follow-up
is 12 months post-randomization.
Our primary aim is to assess the efficacy of m-CCRP in improving the quality of life of ARF survivors at 12 months.
Secondary aims of the study are to evaluate the efficacy of m-CCRP in improving function (cognitive, physical, and
psychological) of ARF survivors and to determine the efficacy of m-CCRP in reducing acute healthcare utilization.
Discussion: The proposed randomized controlled trial will evaluate the efficacy of a collaborative critical care recovery
program in accomplishing the Institute of Healthcare Improvement’s triple aims of better health, better care, at lower cost.
We have developed a collaborative critical care model to promote ARF survivors’ recovery from the physical, psychological,
and cognitive impacts of critical illness. In contrast to a single disease focus and clinic-based access, m-CCRP represents a
comprehensive, accessible, mobile, ahead of the curve intervention, focused on the multiple aspects of the unique
recovery needs of ARF survivors.
Trial registration: NCT03053245, clinicaltrials.gov, registered February 1, 2017.
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Background
With advances in medical technology and an aging popula-
tion, the United States now has millions of acute respiratory
failure (ARF) survivors [1, 2]. Due to illness severity, physio-
logic derangements, procedural and pharmacologic inter-
ventions, invasive mechanical ventilation, and acute brain
dysfunction, ARF survivors are predisposed to experience
post-intensive care syndrome (PICS). PICS is defined as a
cluster of debilitating symptoms characterized by physical
and cognitive impairment as well as symptoms of depres-
sion and anxiety, with a negative impact on their overall
quality of life (QOL) [3–15]. PICS is prevalent, with greater
than 50% of ARF survivors affected, and impairs recovery
after hospital discharge and can persist for years [16, 17].
After an ICU stay, patients are referred to their primary
care provider for follow-up care. Primary care providers
often do not have appropriate resources to identify or treat
PICS symptoms, resulting in diminished QOL and long-
term disability for patients [18, 19–22]. As mentioned
above, more than 50% of ARF survivors suffer from func-
tional or cognitive disability, major or minor depression,
and anxiety.
Rationale for a mobile critical care recovery
program (m-CCRP)
Although community and rehabilitation services are avail-
able to ARF survivors, the fragmented nature of our
healthcare system makes it challenging to coordinate and
direct care to meet the full needs of the patient. This state
of disorganized care for post-ICU PICS patients hinders
their chance for optimal recovery and return to pre-
hospitalization baseline (including employment) [18, 19–
25]. Access to a m-CCRP empowered with tools and sup-
port to integrate and connect essential resources has the
potential to enhance the recovery of ARF survivors.
Existing literature on recovery services for ARF survivors
does not outline a clear path to manage the multiple
comorbidities of PICS. Many of the studies on the subject
have been performed outside the US, limited by small sam-
ple sizes, and failed to address the multidimensional nature
of PICS or had an inadequate follow-up periods [25–27].
We designed our study based on results of the IMPACT
and PREVENT randomized controlled trials, where
interdisciplinary care management for participants suffer-
ing from depression and dementia, respectively, was asso-
ciated with improved outcomes [28, 29]. Participants had
improved QOL (IMPACT) and reduced behavioral and
psychological symptoms (PREVENT). In the GRACE trial,
a care team study using protocols for home-based man-
agement, participants had lower emergency room and
hospital visits, and improved QOL scores in general
health, vitality, social function, and mental health [30].
Given the potential for psychosocial and behavioral effects
of our trial, we used an attention-control comparator arm
to test the specific effects of the intervention [31].
Conceptual model
Our study is aimed at developing a mobile multidisciplin-
ary intervention (m-CCRP) led by a nurse care coordin-
ator to meet the biopsychosocial needs of ARF survivors
with physical, psychological, and cognitive impairment
(Fig. 1). The care coordinator will implement the interven-
tion at the physical residence of the patient and seek to
improve recovery through input from an interdisciplinary
team. The interdisciplinary team is composed of a critical
care physician, a health services scientist, an ICU nurse, a
psychologist, and other consultants as needed to guide the
recovery process over the course of 12 months (Fig. 2).
The recovery process will be informed through dynamic
feedback through process measurement tools and care co-
ordination support software.
Objectives
We sought to answer the following question: Does a
m-CCRP, offering multidisciplinary individualized care plans,
improve the QOL of acute respiratory failure survivors at
12 months?
Primary aim
To assess the efficacy of m-CCRP in improving the QOL of
ARF survivors compared to attention control at 12 months
post hospital discharge.
Secondary aims
Our study has the following secondary aims:
Fig. 1 Conceptual model for m-CCRP study. ARF acute respiratory failure, PICS post-intensive care syndrome
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1. To evaluate the efficacy of m-CCRP in improving
cognitive, physical, and psychological function of
ARF survivors at 12 months post hospital
discharge when compared to attention control.
2. To evaluate the efficacy of m-CCRP in reducing
healthcare utilization, defined as time from
enrollment to emergency department visits
and/or hospital re-admission, by ARF survivors
as compared to attention control at 12 months
post hospital discharge.
Methods/design
Type of trial
The m-CCRP study is a two-arm randomized parallel-
group superiority clinical trial. Patients admitted to the
ICU and diagnosed with ARF are eligible. A total of 620
patients will be randomized (1:1) to one of two arms (310
patients per arm): m-CCRP intervention vs. attention
control.
We chose an attention-control (rather than usual care)
arm to better assess the efficacy of our intervention beyond
behavior modification that is likely to occur within the con-
trolled environment of the trial.
The trial protocol was written according to the Standard
Protocol Items: Recommendations for Interventional Trials
Statement (SPIRIT). A SPIRIT table is provided (Fig. 3),
and a SPIRIT checklist is included in Additional file 1.
Study setting
Patients will be recruited from local tertiary care hospitals
(Indiana University Health Methodist and University Hos-
pitals and Sidney & Lois Eskenazi Hospital). Eskenazi
Hospital is a busy 618-bed, urban, safety net hospital with
44 ICU beds (22 surgical, 22 medical), averaging 120 ICU
admissions per month. The demographics of this ICU are
a mean age of patients 53.7 years, 45% African American,
47% female, 29% aged 60 years or older, and 16% with Me-
dicaid insurance. Methodist Hospital is an urban, quater-
nary care hospital with 802 beds. Patients will be recruited
from three mixed medical and surgical ICU units (65
beds). These ICU units have 153 monthly admissions of
which 48% are females, 47% elderly (age ≥ 60 years), 31%
African Americans, and < 1% with Medicaid insurance.
University hospital is a 257-bed, urban, tertiary care hos-
pital with 18-bed medical and 18-bed surgical ICUs ad-
mitting 50 ICU patients every month. Given the close
affiliation of all centers with the Indiana University School
of Medicine, and the approval of the study under a single
Institutional Review Board (IRB), the need for a coordinat-
ing center or steering committee is not anticipated.
Fig. 2 m-CCRP study timeline. ARF acute respiratory failure, GAD-7 Generalized Anxiety Disorder Scale-7, HABC-M Healthy Aging Brain Center monitor,
HADS Hospital Anxiety and Depression Scale, Katz Katz Index of Independence in Activities of Daily Living, Lawton Lawton Instrumental Activities of
Daily Living, m-CCRP mobile critical care recovery program, MMSE Mini-mental Status Exam, PHQ-9 Patient Health Questionnaire-9, RBANS Repeatable
Battery for Assessment of Neuropsychological Status, SF-36 36-Item Short-Form Survey (Quality of Life), SPPB Short Physical Performance Battery
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Recruitment of participants
The target population for our trial are adults aged 18 years
and older who have been admitted to the medical or
surgical ICUs and are on invasive mechanical ventilation.
Inclusion criteria
Inclusion criteria for our study are (1) age 18 years or
older; (2) hospitalized in the ICU; (3) diagnosed with ARF
requiring greater than or equal to 24 hours of invasive
mechanical ventilation; (4) discharged to home, skilled
nursing facility, sub-acute rehabilitation care, or long-term
acute care; (5) English speaking; (6) able to consent either
in person or through legally authorized representative;
and (7) access to a telephone.
Exclusion criteria
Patients are excluded from the study if they meet any of
the following criteria: (1) hospitalized in a non-ICU ward;
(2) diagnosis of cancer with life expectancy less than 1 year;
(3) admitted with ischemic or hemorrhagic stroke, trau-
matic brain injury (based on the treating physicians’ notes
or evidence of brain injury on neuroimaging), or undergo-
ing neurosurgery; (4) history of dementing illnesses and
other neurodegenerative diseases such as Alzheimer dis-
ease, Parkinson disease, or vascular dementia; (5) unable
to complete study questionnaire due to severe hearing
loss; (6) legally blind; (7) pregnant (assessed by urine or
serum pregnancy test) or nursing; (8) living outside the
greater Indianapolis area; (9) recent history of alcohol or
substance abuse; (10) status post tracheostomy and not
eligible for a speaking valve; and (11) incarcerated at the
time of study enrollment.
Screening, enrollment, and subject randomization
Research staff check the electronic medical records of ICU
patients daily for eligibility. After eligibility is confirmed,
the patient and/or their legal representative are approached
for informed consent. In cases where the participant is not
able to provide consent at the time of screening, consent is
obtained from the surrogate, and the participant is
approached for consent once they are able to consent, and
prior to discharge. The study participant is then random-
ized via a computer-generated randomization scheme to
either the intervention or attention control arm (permuted
block sizes of 6 and 8), stratified by hospital.
Pre-intervention phase
Forty-eight hours prior to hospital discharge and after two
consecutive Confusion Assessment Method negative eval-
uations, research assistants perform blinded in-person
Fig. 3 Standard Protocol Items (SPIRIT) for the m-CCRP Trial. GAD-7 Generalized Anxiety Disorder Scale-7, HADS Hospital Anxiety and Depression Scale, Katz
Katz Index of Independence in Activities of Daily Living, Lawton Lawton Instrumental Activities of Daily Living,m-CCRPmobile critical care recovery program,
MMSE Mini-mental Status Exam, PEG Pain Scale, PHQ-9 Patient Health Questionnaire-9, RBANS Repeatable Battery for Assessment of Neuropsychological Status,
SF-36 36-Item Short-Form Survey (Quality of Life)
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initial evaluations to assess QOL, cognition, physical func-
tion, depression, and anxiety [32–40]. Details regarding
the assessments and outcome measures are discussed
under ‘Outcome assessments’ below.
Intervention phase
m-CCRP intervention
Upon randomization, and after hospital discharge, the care
coordinator will contact patients randomized to the inter-
vention arm. The care coordinator is a registered nurse
whose scope of practice includes health coaching, case
managing, and liaising with community resources and
nursing care providers. The care coordinator reviews
hospital discharge and rehabilitation plans, identifies the
primary care provider, obtains the approval of the primary
care provider to co-manage post ICU care of the eligible
patients, and schedules a face-to-face visit with the patients
at their place of discharge (home, sub-acute rehabilitation
facility/skilled nursing facility or long-term acute care).
First visit The first visit will take place within 1 week of
hospital discharge. The coordinator will assess the
patient’s cognitive, physical, and psychological status. The
coordinator will perform a needs assessment for both the
patient and the caregiver, reconcile all prescribed and
over-the-counter medications, make note of all scheduled
and recommended appointments made at discharge with
specialists and therapists, and assess for community-based
needs. Personalized recovery goals will be discussed with
patients and their caregivers to inform the care plan.
Initial and follow-up visits will be documented in the
care coordination support software, EMR-ABC [41].
Individualized care plans Using the assessments and
information obtained at the first visit, the coordinator will
collaborate with the interdisciplinary team and primary
care physician to finalize the individualized care plan
(Fig. 2). Patients that may benefit from specialty care will
be recommended for specialty evaluation and co-
management. If necessary, the patient will be referred for
a more extensive cognitive and psychological evaluation at
the local mental health practices. This decision will be
jointly reached by the care coordinator, the m-CCRP team
members, the patient, their caregiver, and the patient’s pri-
mary care provider. Finally, a second face-to-face visit
within 2 weeks of the first visit will be arranged.
Second visit During the second visit, the coordinator will
review the individualized recovery care plan with both the
patient and the informal caregiver. This process will include
(1) understanding the diagnoses; (2) process of monitoring
the patient’s recovery; (3) implementation of the appropri-
ate care recovery protocols; (4) distribution and explanation
of the corresponding educational recovery handouts
(patient and informal caregiver); and (5) connection to in-
home services and community resources.
Interaction period The 12-month interaction period will
consist of regular contact between the care coordinator, pa-
tient, and informal caregiver via face-to-face home or clinic
visit, phone contact, email, fax, or mail. During the first
6 months, the minimum amount of contact will be once
every 2 weeks. For the last 6 months, the minimum amount
of contact will be once a month. During these interactions,
the coordinator will answer questions generated from pre-
vious visits, collect patient and caregiver’s feedback, review
and reconcile medications and discuss adherence, review
specialists and therapists appointments and adherence to
care plans, have the patient and the caregiver complete the
HABC Monitor [42] to trigger or modify the use of specific
care recovery protocols, and facilitate the caregiver’s access
to appropriate community resources. The care coordinator
will work with the interdisciplinary team, the patient’s pri-
mary care provider, and specialists to incorporate pa-
tient/caregiver feedback for any revisions needed to the
individualized care plan (Fig. 2).
Care protocols The care coordinator will implement care
protocols developed by our interdisciplinary team. These
protocols have been utilized in the Critical Care Recovery
Center at our institution. These care plans address cogni-
tion, physical function, personal care, mobility, sleep
disturbance, depression, anxiety, agitation or aggression,
delusions or hallucinations, caregiver stress/physical health,
driving safety, nutrition, and medication adherence.
Acute care transition If a patient develops an acute
illness requiring hospitalization, the team activates the
acute care transition phase. The coordinator contacts the
hospital team with relevant information about the patient’s
cognitive, physical and psychological symptoms, and the
patient’s medication list. Upon hospital discharge, the
coordinator conducts a home visit within 72 hours.
Post intervention At the end of 12 months, every patient
will be transitioned to receive full care by their primary
care provider.
Needs assessments during intervention
During the first visit, 1 week after hospital discharge, the
coordinator will assess the patient’s cognitive, physical,
and psychological status using the Mini-mental State
Examination (MMSE) [43] and/or Montreal Cognitive
Assessment (MoCA), Timed up and Go test [44], activities
of daily living (Katz scale) [45], instrumental activities of
daily living (Lawton Scale) [46], Hospital Anxiety and
Depression Scale (HADS) [47], and the Healthy Aging
Brain Care Monitors (HABC-M) [41]. Pain will be
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assessed by the PEG scale [48], and sleep symptoms [49]
measured are also assessed. The HABC-M will also be
used to assess caregiver stress. Initial and follow-up visits
will be documented in care coordination software, the
EMR-ABC.
Attention control
After randomization, subjects assigned to the attention
control group will be contacted by the study research
coordinator to ensure the patient has a primary care phys-
ician appointment at hospital discharge. Patients will
receive a guide for ICU survivors containing phone num-
bers for relevant community resources, education on
caregiver coping skills, and legal and financial advice. An
independent care coordinator/research assistant, not
involved in any outcome assessments, will contact those in
the attention control group by phone. The calls will be
scripted so as to inquire about the patient’s cognitive, phys-
ical, emotional, and general well-being. The frequency of
the calls will mirror the study flow of the intervention
group visits (within 1 week post discharge, within 2 weeks
post first phone call, afterwards twice per month for first
6 months, and once per month for the next 6 months). Pa-
tients will be directed to use the information provided in
the ICU survivor guide to connect with resources. For
those without access to the guide, the relevant phone num-
bers will be provided by telephone and a new guide mailed
within 24 hours of the phone call.
Should an ICU survivor voice concern for any life-
threatening symptoms (severe chest pain, shortness of
breath, bleeding, suicidality), the research assistant will
advise them to present to the emergency room or call emer-
gency medical services, and notify the study investigator.
The primary investigator (a critical care physician) remains
on call for the study, as does a geriatric psychiatrist.
Outcome measures during the study
QOL outcomes
Patient’s health-related QOL will be assessed using the
Medical Outcome Study Short Form (SF-36). This scale
has eight components (physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,
role-emotional, and mental health) that are aggregated
into a Physical Component Summary (PCS) and a Mental
Component Summary (MCS) [32, 33]. Changes that differ
between groups by 2 or more points on a scale of 0 to 100
have been shown to be clinically meaningful.
Cognitive assessment
We will use the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) [35], and the Trail
Making Test Part A and B. The RBANS was developed to
identify and characterize cognitive functioning for adults
aged 12–90 years. It takes 30 minutes to administer and
yields scaled scores for five cognitive domains (Immediate
Memory, Visuospatial Construction, Language, Attention,
and Delayed Memory). The RBANS has excellent reliability
and has been validated across various clinical samples. The
RBANS has four parallel versions, which will be counterba-
lanced across occasions of measurement.
Physical performance
Physical recovery will be assessed via the Short Physical
Performance Battery (SPPB), a validated objective assess-
ment [36]. The SPPB yields a performance score of 0–12
(0–4 poor, 5–7 intermediate, 8–12 good). A difference of
1 point indicates significant change in function. Physical
training and cardiovascular fitness will be assessed using
the 2-minute step test, a validated measure of aerobic
capacity.
Depression and anxiety symptoms
We will use the Patient Health Questionnaire-9 (PHQ-9)
[37, 38] and Generalized Anxiety Disorder Scale (GAD-7)
[39, 40] to determine the impact of the intervention on
ARF survivors’ mood and anxiety. The PHQ-9 is a nine-
item self-report depression scale with a total score from 0
to 27 and the GAD-7 is a seven-item self-report anxiety
scale with a total score from 0 to 21. Both of these scales
are derived from the Patient Health Questionnaire, have
good internal consistency and test–retest reliability, as
well as convergent, construct, criterion, procedural, and
factorial validity for the diagnosis of major depression and
general anxiety disorder. We will use the PTSS-10
questionnaire to assess for post-traumatic stress syndrome
symptoms. The delirium experience questionnaire will be
used to elicit delirium recall.
Acute healthcare utilization
In addition to patient reported emergency department and
hospital admission data, we will use the local data-
warehouse to capture all of the data needed to determine
utilization. Furthermore, we will also use the data from the
Indiana Network for Patient Care (INPC) to complement
any data use outside of our health system. INPC is the
primary health information exchange in the state of Indiana
and it provides data for acute care services from several
major healthcare systems within the state of Indiana. We
will determine the number of emergency department visits
and the number of re-hospitalizations within 12 months of
the index discharge (study follow-up period) as well as the
diagnoses associated with each utilization episode.
Permitted treatments and adherence
Participation in the trial will not preclude any other care
deemed appropriate by the patient’s treating physicians.
Visits and contact time with the participants will be
recorded by the care coordinator as a means of
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monitoring adherence to the intervention protocols. Par-
ticipants randomized to one arm of the trial will not
cross over to another. Participants who wish to decrease
the frequency of their follow-up due to improved health
will still receive the minimum study contact as per
protocol.
Blinding
Research assistants will perform blinded in-person out-
comes assessments similar to the baseline assessment
using the same instruments (SF-36, RBANS, SPPB, PHQ-
9, GAD-7) at 3, 6, and 12 months. We will employ
multiple techniques to ensure concealment of outcomes
assessment [50, 51]. Our research assistants will be trained
not to inquire about study assignments. They will be
conducting structured assessments that do not provide
room for qualitative interviewing that should prevent
unblinding. They will not be involved in study assign-
ments and treatment administrations. Subjects will be
instructed not to discuss their therapy with the research
assistants. Should unblinding occur, other research assis-
tants without knowledge of the participant’s allocation will
be utilized for assessments.
Data collection
Prior to trial initiation, study personnel will undergo
training sessions on data collection and are individually
tested on data entry as well as outcomes assessments.
Study data is collected and managed using Research
Electronic Data Capture (REDCap) tools hosted at Indiana
University [52]. REDCap is a secure, web-based applica-
tion designed to support data capture for research studies,
providing (1) an intuitive interface for validated data entry;
(2) audit trails for tracking data manipulation and export
procedures; (3) automated export procedures for seamless
data downloads to common statistical packages; and (4)
procedures for importing data from external sources.
Data dissemination
Access to the final dataset will be retained with the study
investigators. Compensation for the trial, including harm,
is not intended. Results of the trial are intended for publi-
cation in a peer-reviewed journal by the authors, and
assistance of professional writers is not expected. Results
will be shared with participants of the study by e-mail,
and within our hospital system. Granting full access to the
protocol or participant-level dataset is not intended.
Monitoring
Monitoring will be performed by an independent data
safety monitoring board (DSMB) consisting of three mem-
bers with expertise in critical care, clinical geriatrics, clinical
trial methodology, and biostatistics. The DSMB will receive
trial data from the biostatistician and choose to continue
the study as planned, change the study protocol, or stop the
trial early for harm. The DSMB will review trial data with
the m-CCRP statistician in a closed session upon enroll-
ment of 30 patients, and at least once every 12 months.
DSMB members will delete or shred any files they receive
for the review meetings. Meeting minutes and related data
from each DSMB meeting will be retained in a secured file
for inspection by regulatory authorities.
Adverse events
Clinical outcomes, including death, will be systematically
tracked and included in the safety and efficacy analyses
for the study. Death will not be recorded as an adverse
event unless the investigator believes the event may have
been related to the study protocol. Other clinical out-
comes tracked include hospital or ICU readmissions,
depressive symptoms, anxiety, agitation and behavioral
disturbances, and fall and mobility problems, and will be
categorized as adverse events if related to the study proto-
col. Serious adverse events include death, life-threatening
episode requiring immediate intervention, inpatient
hospitalization, persistent or significant incapacitation,
and an episode requiring intervention to prevent perman-
ent impairment/damage.
The study manager will monitor adverse events, and the
principal investigator will be notified within 24 hours of
identifying an occurrence. Serious and unexpected adverse
events will be reported to the IRB, safety officer, DSMB,
and NIH. Non-serious adverse events will be reported to
the IRB as part of a continuing review. Unanticipated
problems will also be reported.
Stopping guidelines
The trial can be prematurely paused or closed by the
DSMB in order to evaluate safety information from the
study, or if there is evidence of harm in the study.
Statistical analysis
We will compare randomization results to pre-planned
randomization schedule to ensure randomization integrity.
To verify the comparability of the randomized groups,
patients’ baseline characteristics between the intervention
and the usual care group will be compared using t-tests or
Wilcoxon rank-sum tests for continuous variables and χ2
tests for categorical variables. All analyses will be conducted
using SAS 9.4 software.
Primary aim Mixed effects models will be used with
repeated SF-36 PCS and MCS collected at baseline, and
at 3, 6, and 12 months as the outcome measures, using
group, time, and interactions between group and time as
independent variables while adjusting for randomization
stratum and other potential baseline covariates. An un-
structured variance–covariance matrix will be used in
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the mixed effects models to adjust for the potential cor-
relations among PCS or MCS obtained from the same
individual over time. Post-hoc comparisons using linear
contrasts will be conducted following a significant inter-
action between group and time to determine the earliest
time when a group difference can be detected. Parameter
estimation and inference for the mixed-effects models are
conducted using the maximum likelihood approach,
which yields robust parameter estimation and inference
under many missing data mechanisms [53]. We will also
include additional covariates to examine whether patients’
characteristics, severity of illness, or prior medical comor-
bidities are associated with the changes in QOL measures.
Secondary aim 1 Mixed effects models will be used with
repeated cognitive (RBANS), physical (SPPB), depression
(PHQ-9), or anxiety (GAD-7) measures collected at base-
line, and at 3, 6, and 12 months as the outcome measures,
using group, time, and interactions between group and time
as independent variables while adjusting for randomization
stratum and other potential baseline covariates, similarly to
the analysis plan described for the primary aim. In addition,
we will use mixed effect models with PCS and MCS as the
dependent variables and cognitive, physical, and psycho-
logical functions as the independent variables to determine
how changes in specific functional domains relate to
changes in health-related QOL.
Secondary aim 2 Time from enrollment to emergency
department visits and hospital readmissions will be used as
the outcome variables in Cox’s proportional hazards
models and group as the independent variable while
adjusting for randomization stratum and other covariates.
Patients who are followed to 12 months without experien-
cing any event will have their event time censored at
12 months; patients who died or were lost to follow-up will
have their observation time censored at the time of death
or date of last contact. Recurring events will be modeled
using the Andersen–Gill model for multiple events using
elapsed times with robust variance [54]. We will examine
the proportional hazard assumption by including the inter-
action between the group indicator variable and time. We
will also include other patients’ characteristics, illness se-
verity and other comorbidities in the model to determine
whether intervention effect is affected by other covariates.
Sample size justification Based on our preliminary data
in this patient population, we anticipate that 16% will die
during follow-up and another 20% will be lost to follow-
up. Thus, we estimate that we will have 400 patients com-
pleting the 12-month follow-up (200 patients per group).
A previous study in ICU survivors reported a mean PCS
increase from 29.0 (SD= 13.4) to 35.4 (SD= 11.8) and mean
MCS increase from 44.6 (SD= 10.8) to 45.8 (SD= 10.6) [55].
Assuming patients in the usual care group follows the
trajectory reported in Sukantarat et al. [55], 200 patients per
group with completed follow-up data will provide 80%
power to detect a difference of 0.28 SD in mean PCS or
MCS at the 12-month follow-up using a two-sample t-test
at α = 0.05. The projected effect size translates to approxi-
mately 3.3 points higher in PCS and 3.0 points higher in
MCS for patients in the intervention group compared to
those in the attention control at the end of intervention
using the standard deviations reported in Sukantarat et al.
[55]. Based on previous literature, we assume a baseline
mean RBANS score of 79 (SD 11.85) [56]. The sample size
of 200 patients per group will provide 80% power to detect
a difference of 3.3 in RBANS scores between the two groups
at 12 months assessment using a two-sample t-test at α =
0.05. Similarly, with a baseline mean SPPB score of 6.0 (SD
= 2.5) in this patient population [36], our sample size will
yield 80% power to detect a difference of 0.7 in SPPB scores
during the 12-month intervention period. We are also pow-
ered to detect 0.28 SD in reduction in PHQ-9 and GAD-7
scores at the end of intervention. For power estimation of
acute care utilization, we will have access to the electronic
medical records of all enrolled patients (n = 620). Assuming
a probability of 40% for emergency room visit or
hospitalization for patients in the usual care group during
the 12-month follow-up, we will have 80% power to detect a
hazard ratio of 0.64 or lower for reduction in emergency
room visits or hospitalization using log rank test at α = 0.05.
Discussion
The proposed randomized controlled trial will evaluate
the efficacy of a collaborative critical care recovery pro-
gram in accomplishing the Institute of Healthcare Im-
provement’s triple aims of better health, better care, at
lower cost [57]. Our study is innovative in several ways.
We have developed a collaborative critical care model to
promote ARF survivors’ recovery from the physical, psy-
chological and cognitive impacts of critical illness. In
contrast to a single disease focus and clinic-based access,
m-CCRP represents a comprehensive, accessible, mobile,
ahead of the curve intervention focused on the multiple
aspects of the unique recovery needs of ARF survivors.
Previous studies in other conditions found that discon-
necting the needs assessment from its subsequent man-
agement reduced the impact of such assessment [38]. The
m-CCRP study couples comprehensive evaluation of ARF
survivors with an interdisciplinary management program
and delivers it in a bundled plan of care. At the same time,
the individual goals of the patients and caregivers will be
incorporated to form an individualized care plan. The care
coordinator will identify and work towards ARF survivors’
and caregivers’ target goals by delivering individualized
care plans and by tracking effectiveness of intervention.
This will enhance survivors’ retention in the program and
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will provide regular feedback. Our care coordination sup-
port software [42] and the Healthy Aging Brain Care mon-
itors will provide dynamic and actionable feedback to
assess ARF survivors’ recovery in a timely manner.
The resultant adjustments in the care plans are highly
desirable for the frequently changing acute needs of
ARF survivors, compared to the relatively stable
chronic care needs of older adults.
Finally, m-CCRP will deliver care to the patient at
home, rehab facility, or at their primary care or special-
ists offices. This obviates the need for excess travel by
recovering ARF survivors.
As with all studies, we anticipate that there will be
potential problems. First and foremost, recruitment in
clinical trials is challenging in the ICU. Our team has
developed an ICU research infrastructure that has
allowed us to successfully recruit ICU patients as previ-
ously mentioned in our preliminary work.
Secondly, a longer follow-up poses a challenge in
retention of subjects. We plan to mitigate withdrawals
from both groups through several mechanisms. Quality
control procedures allow us to monitor subjects’ percep-
tions about the risks and benefits of participation. We
will recruit research personnel representatives of the
target population by sex and race and provide training
to work with vulnerable research populations. Retention
will be periodically measured. If retention drops below
80%, we will have study staff follow-up with the study
participants to troubleshoot issues and provide coaching.
Gift card incentives will be instituted using fair subject
payments to maximize participation.
While the proposed intervention has multiple com-
ponents, the study is not designed to test which of
these components is most efficacious. Caring for PICS
patients is a multidisciplinary and multidimensional
responsibility, and we do not believe that isolating one
component is likely to improve care of these patients. Our
research team’s capacity to design, deliver and measure
outcomes for a multi-component intervention is one of
our key strengths.
Trial status
Enrollment is ongoing. Recruitment started in March 2017
and is expected to conclude January 2020. Target enroll-
ment for the study is 620 subjects.
Protocol version
Version 1.0, 09182016.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documentsa. aIt is strongly recommended
that this checklist be read in conjunction with the SPIRIT 2013 Explanation &
Elaboration for important clarification on the items. Amendments to the
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by
the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-
NoDerivs 3.0 Unported” license. (DOCX 24 kb)
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